Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL
- PMID: 30824485
- DOI: 10.1158/2159-8290.CD-19-0029
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL
Abstract
In this issue, Blombery and colleagues show that the chronic lymphocytic leukemia (CLL) cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells. Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL.See related article by Blombery et al., p. 342.
©2019 American Association for Cancer Research.
Comment on
-
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4. Cancer Discov. 2019. PMID: 30514704
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources